GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Short-Term Debt

Access Bio (XKRX:950130) Short-Term Debt : ₩14,690 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio Short-Term Debt?

Access Bio's Short-Term Debt for the quarter that ended in Dec. 2024 was ₩14,690 Mil.

Access Bio's quarterly Short-Term Debt declined from Jun. 2024 (₩9,123 Mil) to Sep. 2024 (₩120 Mil) but then increased from Sep. 2024 (₩120 Mil) to Dec. 2024 (₩14,690 Mil).

Access Bio's annual Short-Term Debt increased from Dec. 2022 (₩9,004 Mil) to Dec. 2023 (₩9,083 Mil) and increased from Dec. 2023 (₩9,083 Mil) to Dec. 2024 (₩14,690 Mil).


Access Bio Short-Term Debt Historical Data

The historical data trend for Access Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Short-Term Debt Chart

Access Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33,518.97 56,141.90 9,003.72 9,082.67 14,690.00

Access Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,082.67 9,102.65 9,122.84 120.00 14,690.00

Access Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Access Bio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Access Bio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines